Evommune(EVMN)

盘后27.90-0.56-1.97%19:56 EST

28.46-0.57-1.96%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
Evommune
所属市场
NYSE
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.evommune.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Evommune, Inc.是一家于2020年4月在特拉华州注册成立的公司，总部位于加利福尼亚州的帕洛阿尔托。该公司是一家临床阶段的生物技术公司，专注于针对慢性炎症疾病主要致病因素的创新治疗方案开发。其初步临床开发项目集中在慢性自发性荨麻疹、特应性皮炎和溃疡性结肠炎上。
- 02-10 13:00
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-12-11
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-12-11
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-07
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-11-07
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-06
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

分时
5日
日
周
月

数据加载中...

最高

29.64

今开

28.38

量比

0.38

最低

24.12

昨收

29.03

换手率

13.42%

热议股票

{"pagemeta":{"title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Evommune,EVMN,Evommune股票,Evommune股票老虎,Evommune股票老虎国际,Evommune行情,Evommune股票行情,Evommune股价,Evommune股市,Evommune股票价格,Evommune股票交易,Evommune股票购买,Evommune股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"EVMN","data":{"stockData":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":28.46,"timestamp":1770843600000,"preClose":29.03,"halted":0,"volume":1261461,"hourTrading":{"tag":"盘后","latestPrice":27.9,"preClose":28.46,"latestTime":"19:56 EST","volume":8406,"amount":234098.3994,"timestamp":1770857819138,"change":-0.56,"changeRate":-0.019677,"amplitude":0.039353},"delay":0,"changeRate":-0.019634860489149166,"floatShares":9400000,"shares":31524093,"eps":-1.993,"marketStatus":"未开盘","change":-0.57,"latestTime":"02-11 16:00:00 EST","open":28.38,"high":29.64,"low":24.12,"amount":33757759.771623,"amplitude":0.190148,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.993,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":0,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":29.03,"preHourTrading":{"tag":"盘前","latestPrice":28.03,"preClose":29.03,"latestTime":"09:29 EST","volume":22668,"amount":639745.9299,"timestamp":1770820180452,"change":-1,"changeRate":-0.034447,"amplitude":0.056493},"postHourTrading":{"tag":"盘后","latestPrice":27.9,"preClose":28.46,"latestTime":"19:56 EST","volume":8406,"amount":234098.3994,"timestamp":1770857819138,"change":-0.56,"changeRate":-0.019677,"amplitude":0.039353},"volumeRatio":0.37534},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.510884059775392","cardData":[{"tweetId":"510884059775392","author":{"authorId":"3452938437060827","idStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6595,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"超22亿元，年内规模最大的生物医药IPO诞生","digest":"2025年11月，在生物医药领域，有2家公司以IPO的方式赴美上市，市场较为清淡。 但从募集规模来看，11月上市的BillionToOne位列今年第一大规模的生物医药IPO，超过了9月上市的LB Pharmaceuticals（2.85亿美元）、1月上市的Metsera（2.75亿美元）。 图片 1、Evommune(NYSE:EVMN) 11月7日，Evommune在纽约交易所上市，发行价为每股16美元，发行937.5万股，融资规模达1.5亿美元。 Evommune成立于2020年，是一家成专注于开发治疗免疫介导炎症性疾病药物公司。创始团队来自被礼来以11亿美元收购的皮肤病药物公司Dermira(NASDAQ:DERM)。 目前，Evommune共有两个个在研药物： EVO756：一款强效且高选择性的MRGPRX2口服小分子拮抗剂。靶标MRGPRX2是G蛋白偶联受体（GPCR）家族成员，主要表达于肥大细胞表面，其激活机制与经典IgE介导的过敏反应不同，属于“非经典激活”通路。该受体可被多种内源性（如神经肽、抗菌肽）和外源性（如药物、化学刺激物）配体激活，触发肥大细胞脱颗粒，释放组胺、蛋白酶等炎症介质，导致伪过敏反应、慢性炎症及瘙痒等症状。 EVO756的主要适应症是慢性荨麻疹，今年5月发布的临床2期研究显示，300mg每日一次或50mg每日两次给药4周后，总体改善率达 93%，瘙痒评分（Pruritus NRS）较基线下降约50%，在安全性和药效上均达到慢性荨麻疹治疗的主要治疗终点。此外，EVO756还于8月启动特应性皮炎的临床二期研究。 EVO301：一款长效融合蛋白，由IL-18结合蛋白（IL-18BP）与抗血清白蛋白Fab相关结构域组成。该药物由韩国生物技术公司AprilBio授权，Evommune于2024年获得许可。IL-18是IL-1家族的一种促炎性细胞因子，","plainDigest":"2025年11月，在生物医药领域，有2家公司以IPO的方式赴美上市，市场较为清淡。 但从募集规模来看，11月上市的BillionToOne位列今年第一大规模的生物医药IPO，超过了9月上市的LB Pharmaceuticals（2.85亿美元）、1月上市的Metsera（2.75亿美元）。 图片 1、Evommune(NYSE:EVMN) 11月7日，Evommune在纽约交易所上市，发行价为每股16美元，发行937.5万股，融资规模达1.5亿美元。 Evommune成立于2020年，是一家成专注于开发治疗免疫介导炎症性疾病药物公司。创始团队来自被礼来以11亿美元收购的皮肤病药物公司Dermira(NASDAQ:DERM)。 目前，Evommune共有两个个在研药物： EVO756：一款强效且高选择性的MRGPRX2口服小分子拮抗剂。靶标MRGPRX2是G蛋白偶联受体（GPCR）家族成员，主要表达于肥大细胞表面，其激活机制与经典IgE介导的过敏反应不同，属于“非经典激活”通路。该受体可被多种内源性（如神经肽、抗菌肽）和外源性（如药物、化学刺激物）配体激活，触发肥大细胞脱颗粒，释放组胺、蛋白酶等炎症介质，导致伪过敏反应、慢性炎症及瘙痒等症状。 EVO756的主要适应症是慢性荨麻疹，今年5月发布的临床2期研究显示，300mg每日一次或50mg每日两次给药4周后，总体改善率达 93%，瘙痒评分（Pruritus NRS）较基线下降约50%，在安全性和药效上均达到慢性荨麻疹治疗的主要治疗终点。此外，EVO756还于8月启动特应性皮炎的临床二期研究。 EVO301：一款长效融合蛋白，由IL-18结合蛋白（IL-18BP）与抗血清白蛋白Fab相关结构域组成。该药物由韩国生物技术公司AprilBio授权，Evommune于2024年获得许可。IL-18是IL-1家族的一种促炎性细胞因子，","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765761963467,"gmtModify":1765763345678,"symbols":["NVDA","QQQ","EVMN","BLLN","XBI"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/f6a3e026bf6fef3565e7d0d413ea494c","width":"1038","height":"137"},{"url":"https://static.tigerbbs.com/5a26cb7daea4fc7076003c24e17cce02","width":"1080","height":"381"},{"url":"https://static.tigerbbs.com/0ef74c65765d6ddab0964683dfd1805d","width":"1000","height":"517"}],"repostCount":0,"viewCount":1945,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/510884059775392","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":5512,"displayRows":4,"foldSize":0,"authorId":"3452938437060827"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.498632219562376","cardData":[{"tweetId":"498632219562376","author":{"authorId":"36979109942400","idStr":"36979109942400","name":"小虎周报","avatar":"https://static.laohu8.com/f7b172cf773c77a3f0df67695c126b51","userType":4,"introduction":"老虎股票官方帐号","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":565788,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【一周IPO观察】新股“冰火两重天”，“二进宫”受挫；海伟电子过讯，10股递表；美股科技医药表现亮眼","digest":"港股IPO观察截止2025年的第45周，港交所7家上市，7家招股，1家聆讯，10家递表当周上市（7家，其中1家转板）数据智能应用软件供应商 <a href=\"https://laohu8.com/S/02718\">$明略科技-W(02718)$</a> （首日+106.10%）新能源汽车龙头企业 <a href=\"https://laohu8.com/S/09927\">$赛力斯(09927)$</a> （首日+0）生殖健康生物医药公司 <a href=\"https://laohu8.com/S/02630\">$旺山旺水-B(02630)$</a> （首日+145.73%）L4级自动驾驶领域的全球先行者 <a href=\"https://laohu8.com/S/00800\">$文远知行-W(00800)$</a> （首日-9.96%）Robotaxi公司 <a href=\"https://laohu8.com/S/02026\">$小马智行-W(02026)$</a> （首日-9.28%）A+H智能汽车科技解决方案提供商 <a href=\"https://laohu8.com/S/00699\">$均胜电子(00699)$</a> （首日-8.00%） <a href=\"https://laohu8.com/S/09876\">$大洋环球控股(09876)$</a> 成功从GEM转至主板上市当周招股（3家新） <a href=\"https://laohu8.com/S/02698\">$乐舒适(02698)$</a> <a href=\"https://laohu8.com/S/02579\">$中伟新材(02579)$</a> <a href=\"https://laohu8.com/S/02615\">$百利天恒(02615)$</a> 通过聆讯（2家）中国第二大的电容器薄膜制造商海伟","plainDigest":"港股IPO观察截止2025年的第45周，港交所7家上市，7家招股，1家聆讯，10家递表当周上市（7家，其中1家转板）数据智能应用软件供应商 $明略科技-W(02718)$ （首日+106.10%）新能源汽车龙头企业 $赛力斯(09927)$ （首日+0）生殖健康生物医药公司 $旺山旺水-B(02630)$ （首日+145.73%）L4级自动驾驶领域的全球先行者 $文远知行-W(00800)$ （首日-9.96%）Robotaxi公司 $小马智行-W(02026)$ （首日-9.28%）A+H智能汽车科技解决方案提供商 $均胜电子(00699)$ （首日-8.00%） $大洋环球控股(09876)$ 成功从GEM转至主板上市当周招股（3家新） $乐舒适(02698)$ $中伟新材(02579)$ $百利天恒(02615)$ 通过聆讯（2家）中国第二大的电容器薄膜制造商海伟","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1762744473080,"gmtModify":1763597091732,"symbols":["02718","02698","09927","02630","02615","00699","02579","BETA","EVMN","AERO","300972","002311","688136","02026","00800","XZO","Q","09876","BLLN","DTCK","YUMC","09609","09987","600699","601127","WRD","688506"],"themeIds":["d3be30bf50ef48a996b040d382c5af8e","0e78c0db8cb445f7b26f2b55e79c0399","a38bd418a0044ecaa74d64a17b49e148"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/80d5dc3eb82b0e9bb85158a49aef6e5e"}],"repostCount":0,"viewCount":30030,"likeCount":6,"liked":false,"collected":false,"commentCount":1,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/498632219562376","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":6069,"displayRows":4,"foldSize":0,"authorId":"36979109942400"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.496161246818552","cardData":[{"tweetId":"496161246818552","author":{"authorId":"36979109942400","idStr":"36979109942400","name":"小虎周报","avatar":"https://static.laohu8.com/f7b172cf773c77a3f0df67695c126b51","userType":4,"introduction":"老虎股票官方帐号","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":565788,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【一周IPO观察】新股续涨，明略暗盘翻倍，乐舒适招股，33股港股递表；杜邦分拆Q上市，军工科技BETA本周美股上市","digest":"港股IPO观察截止2025年的第44周，港交所4家上市，5家招股，2家聆讯，25家递表当周上市（3家） <a href=\"https://laohu8.com/S/01384\">$滴普科技(01384)$</a> （首日+20.6%） <a href=\"https://laohu8.com/S/06166\">$剑桥科技(06166)$</a> （首日+36.90%） <a href=\"https://laohu8.com/S/06980\">$八马茶业(06980)$</a> （首日+78.80%） <a href=\"https://laohu8.com/S/06031\">$三一重工(06031)$</a> （首日-2.44%）当周招股（7家）数据智能应用软件供应商 <a href=\"https://laohu8.com/S/02718\">$明略科技-W(02718)$</a> （暗盘+110.64%）新能源汽车龙头企业 <a href=\"https://laohu8.com/S/09927\">$赛力斯(09927)$</a> 生殖健康生物医药公司 <a href=\"https://laohu8.com/S/02630\">$旺山旺水-B(02630)$</a> L4级自动驾驶领域的全球先行者 <a href=\"https://laohu8.com/S/00800\">$文远知行-W(00800)$</a> Robotaxi公司 <a href=\"https://laohu8.com/S/02026\">$小马智行-W(02026)$</a> A+H智能汽车科技解决方案提供商 <a href=\"https://laohu8.com/S/00699\">$均胜电子(00699)$</a> 跨国卫生用品公司乐舒适通过聆讯（2家）跨国卫生用品公司","plainDigest":"港股IPO观察截止2025年的第44周，港交所4家上市，5家招股，2家聆讯，25家递表当周上市（3家） $滴普科技(01384)$ （首日+20.6%） $剑桥科技(06166)$ （首日+36.90%） $八马茶业(06980)$ （首日+78.80%） $三一重工(06031)$ （首日-2.44%）当周招股（7家）数据智能应用软件供应商 $明略科技-W(02718)$ （暗盘+110.64%）新能源汽车龙头企业 $赛力斯(09927)$ 生殖健康生物医药公司 $旺山旺水-B(02630)$ L4级自动驾驶领域的全球先行者 $文远知行-W(00800)$ Robotaxi公司 $小马智行-W(02026)$ A+H智能汽车科技解决方案提供商 $均胜电子(00699)$ 跨国卫生用品公司乐舒适通过聆讯（2家）跨国卫生用品公司","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1762141135168,"gmtModify":1762141418028,"symbols":["DD","02718","02698","09927","02630","00699","BETA","NOMA","EVMN","01384","06031","AERO","BGSI","02026","00800","XZO","MPLT","NAVN","300919","BLLN","06166","06980","603083","600031","600699","601127","WRD"],"themeIds":["305e2bf187774c7ba2efccb8bf887850","d3be30bf50ef48a996b040d382c5af8e","0e78c0db8cb445f7b26f2b55e79c0399"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/80d5dc3eb82b0e9bb85158a49aef6e5e"}],"repostCount":4,"viewCount":38709,"likeCount":9,"liked":false,"collected":false,"commentCount":1,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/496161246818552","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":9181,"displayRows":4,"foldSize":0,"authorId":"36979109942400"}],"position":0}],"size":3},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20719419","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526043771-EVMN","pdf_url":"","pub_time":1770699600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"EVMN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/0001193125-26-043771-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_1.htm","primary":true,"translateUrl":"","linkName":"evmn-ex99_1.htm","type":"EX-99.1","id":"NTFILE5t8nJ85zVre3ZUGa","market":"us","size":31656},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-20260210.htm","primary":false,"translateUrl":"","linkName":"evmn-20260210.htm","type":"8-K","id":"NTFILECHDTdjHMJe2B9FfT","market":"us","size":61795},{"description":"EX-99.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2.htm","primary":false,"translateUrl":"","linkName":"evmn-ex99_2.htm","type":"EX-99.2","id":"NTFILE7KQp8MUZTa3kzuVR","market":"us","size":27407},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/img108483603_0.jpg","primary":false,"translateUrl":"","linkName":"img108483603_0.jpg","type":"GRAPHIC","id":"NTFILE37nThAPipKzdSotz","market":"us","size":645024},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/img108483603_1.gif","primary":false,"translateUrl":"","linkName":"img108483603_1.gif","type":"GRAPHIC","id":"NTFILECMavFwD3zS66rkNz","market":"us","size":21982},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/img115706865_0.gif","primary":false,"translateUrl":"","linkName":"img115706865_0.gif","type":"GRAPHIC","id":"NTFILEFvjxUSoE1sVoq3jk","market":"us","size":21982},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s1.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s1.jpg","type":"GRAPHIC","id":"NTFILEBKv18wPw32nWAdRP","market":"us","size":215059},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s2.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s2.jpg","type":"GRAPHIC","id":"NTFILE3tyhFsctHJuhF5yg","market":"us","size":686202},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s3.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s3.jpg","type":"GRAPHIC","id":"NTFILE6KZwDBkzJkNH1j4A","market":"us","size":335741},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s4.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s4.jpg","type":"GRAPHIC","id":"NTFILEHrGa8p3ME9GJhL5S","market":"us","size":436793},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s5.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s5.jpg","type":"GRAPHIC","id":"NTFILE21Q3y7S2ygVu3vLM","market":"us","size":319632},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s6.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s6.jpg","type":"GRAPHIC","id":"NTFILEHBRAGTsBZMkwrnvF","market":"us","size":389465},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s7.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s7.jpg","type":"GRAPHIC","id":"NTFILEAmqnHkx9Ga3s6y9U","market":"us","size":320834},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s8.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s8.jpg","type":"GRAPHIC","id":"NTFILE9SbhK66uvPrJK3FN","market":"us","size":257762},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s9.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s9.jpg","type":"GRAPHIC","id":"NTFILE6XwXNq9CKSe4kov6","market":"us","size":423651},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s10.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s10.jpg","type":"GRAPHIC","id":"NTFILE7H8Yid8GnzFqf77x","market":"us","size":281261},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s11.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s11.jpg","type":"GRAPHIC","id":"NTFILE8JXYYLXjYz4hyGZx","market":"us","size":297034},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s12.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s12.jpg","type":"GRAPHIC","id":"NTFILECwcJ5D8Y12r3qGxA","market":"us","size":299979},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s13.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s13.jpg","type":"GRAPHIC","id":"NTFILE2C5ozKoRN3zFksQZ","market":"us","size":271101},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s14.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s14.jpg","type":"GRAPHIC","id":"NTFILEEgiAHL9HA3HwLpke","market":"us","size":244320},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s15.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s15.jpg","type":"GRAPHIC","id":"NTFILEd3iHRVwJUHEbNuoj","market":"us","size":382333},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s16.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s16.jpg","type":"GRAPHIC","id":"NTFILEDj28P8raQnpq7vMv","market":"us","size":243399},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s17.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s17.jpg","type":"GRAPHIC","id":"NTFILE78haQnwY9W4DgZvv","market":"us","size":301293},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s18.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s18.jpg","type":"GRAPHIC","id":"NTFILECc855hPyQnHuAap8","market":"us","size":374121},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s19.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s19.jpg","type":"GRAPHIC","id":"NTFILEEFZsZoizuYSnjfiv","market":"us","size":405317},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s20.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s20.jpg","type":"GRAPHIC","id":"NTFILE3Yz7xi3AHJM1zucZ","market":"us","size":424037},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s21.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s21.jpg","type":"GRAPHIC","id":"NTFILE5dzk1ZodvcfykC9M","market":"us","size":305120},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s22.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s22.jpg","type":"GRAPHIC","id":"NTFILEE7YP1YPBe8AN8mnf","market":"us","size":142842},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s23.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s23.jpg","type":"GRAPHIC","id":"NTFILE5zYWrXQXWc1X34CK","market":"us","size":146300},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s24.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s24.jpg","type":"GRAPHIC","id":"NTFILECUf8yFhoK7XQDrTE","market":"us","size":418357},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s25.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s25.jpg","type":"GRAPHIC","id":"NTFILECtP2iV1MF17ndmWf","market":"us","size":342815},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s26.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s26.jpg","type":"GRAPHIC","id":"NTFILESb7yofYqXhY5sNto","market":"us","size":278933},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-ex99_2s27.jpg","primary":false,"translateUrl":"","linkName":"evmn-ex99_2s27.jpg","type":"GRAPHIC","id":"NTFILE8rbmo7Qe1gzr7fgQ","market":"us","size":269941}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-10 13:00","pubTimestamp":1770699600,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20520033","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525315972-EVMN","pdf_url":"","pub_time":1765429200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"EVMN","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315972/0001193125-25-315972-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315972/evmn-20250930.htm","primary":true,"translateUrl":"","linkName":"evmn-20250930.htm","type":"10-Q","id":"NTFILE5hVdPWdsArqGWy3H","market":"us","size":3099560},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315972/evmn-ex31_1.htm","primary":false,"translateUrl":"","linkName":"evmn-ex31_1.htm","type":"EX-31.1","id":"NTFILECJbxsFx9n4sAQN51","market":"us","size":20698},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315972/evmn-ex31_2.htm","primary":false,"translateUrl":"","linkName":"evmn-ex31_2.htm","type":"EX-31.2","id":"NTFILEE1jJH1Br8X74rpGJ","market":"us","size":22039},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315972/evmn-ex32_1.htm","primary":false,"translateUrl":"","linkName":"evmn-ex32_1.htm","type":"EX-32.1","id":"NTFILE6NYTdcnp7vywhD4U","market":"us","size":19884}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-12-11 13:00","pubTimestamp":1765429200,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20519921","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525315918-EVMN","pdf_url":"","pub_time":1765429200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"EVMN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/0001193125-25-315918-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-ex99_1.htm","primary":true,"translateUrl":"","linkName":"evmn-ex99_1.htm","type":"EX-99.1","id":"NTFILECAGeCGTmyDxBSZXU","market":"us","size":199388},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-20251211.htm","primary":false,"translateUrl":"","linkName":"evmn-20251211.htm","type":"8-K","id":"NTFILECk1yXgLnmcSc6TKo","market":"us","size":52036},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/img108483603_0.jpg","primary":false,"translateUrl":"","linkName":"img108483603_0.jpg","type":"GRAPHIC","id":"NTFILEEGxxt123PUzTYh6e","market":"us","size":645024}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-12-11 13:00","pubTimestamp":1765429200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20440179","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525272519-EVMN","pdf_url":"","pub_time":1762491600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"EVMN","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/0001193125-25-272519-index.htm","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726ds8.htm","primary":true,"translateUrl":"","linkName":"d78726ds8.htm","type":"S-8","id":"NTFILEaS6r7gAeyRHjRZpb","market":"us","size":54466},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726dex51.htm","primary":false,"translateUrl":"","linkName":"d78726dex51.htm","type":"EX-5.1","id":"NTFILEB9NZv7VekhYms79Y","market":"us","size":9408},{"description":"EX-23.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726dex231.htm","primary":false,"translateUrl":"","linkName":"d78726dex231.htm","type":"EX-23.1","id":"NTFILEEoTGz5oVg9mJvMvW","market":"us","size":2447},{"description":"EX-99.3","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726dex993.htm","primary":false,"translateUrl":"","linkName":"d78726dex993.htm","type":"EX-99.3","id":"NTFILE8x5ELedXCDEUgkoK","market":"us","size":171075},{"description":"EX-FILING FEES","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726dexfilingfees.htm","primary":false,"translateUrl":"","linkName":"d78726dexfilingfees.htm","type":"EX-FILING FEES","id":"NTFILEA1CoiCdjMUjfKA5o","market":"us","size":25684},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/g78726g1105031828064.jpg","primary":false,"translateUrl":"","linkName":"g78726g1105031828064.jpg","type":"GRAPHIC","id":"NTFILEGEJscydaayxH9wJw","market":"us","size":2403}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2025-11-07 13:00","pubTimestamp":1762491600,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20440102","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525272282-EVMN","pdf_url":"","pub_time":1762491600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"EVMN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272282/0001193125-25-272282-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-3.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272282/d38367dex31.htm","primary":true,"translateUrl":"","linkName":"d38367dex31.htm","type":"EX-3.1","id":"NTFILE7ynA5aPWk3en2jxc","market":"us","size":27615},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525272282/d38367d8k.htm","primary":false,"translateUrl":"","linkName":"d38367d8k.htm","type":"8-K","id":"NTFILEEpYpznsF4cabL4Qw","market":"us","size":25387}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-07 13:00","pubTimestamp":1762491600,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.03项：公司章程或章程的修订；财政年度的变化；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20440105","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525267581-EVMN","pdf_url":"","pub_time":1762405200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses","symbol":"EVMN","title":"Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses","titleType":"[补充]招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525267581/0001193125-25-267581-index.htm","us_notice_code":"Form FWP","us_title_en":"Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FWP","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525267581/d941543dfwp.htm","primary":true,"translateUrl":"","linkName":"d941543dfwp.htm","type":"FWP","id":"NTFILEHw3TLzMsvNQ3Z8Py","market":"us","size":9942}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"[Supp]Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[补充]招股说明书","pubTime":"2025-11-06 13:00","pubTimestamp":1762405200,"title_zh":"Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.evommune.com","stockEarnings":[{"period":"1week","weight":0.5026},{"period":"1month","weight":0.3463},{"period":"3month","weight":0.562},{"period":"6month","weight":0.7788},{"period":"ytd","weight":0.6624}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Evommune, Inc.是一家于2020年4月在特拉华州注册成立的公司，总部位于加利福尼亚州的帕洛阿尔托。该公司是一家临床阶段的生物技术公司，专注于针对慢性炎症疾病主要致病因素的创新治疗方案开发。其初步临床开发项目集中在慢性自发性荨麻疹、特应性皮炎和溃疡性结肠炎上。","exchange":"NYSE","name":"Evommune","nameEN":"Evommune"},"aProfile":null}}}